News

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.

Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.

Ahmad Masri, MD, MS, highlights HCM agents to watch in 2027, including sotagliflozin and EDG-7500, and how MAPLE-HCM challenged beta-blocker use.

Ahmad Masri, MD, MS, discusses the move toward medical therapy in HCM, the nonobstructive treatment gap, and imaging's role in diagnosis and follow-up.

Pavel Strnad, MD, discusses pooled phase 2 data showing fazirsiran cut liver Z-AAT burden by about 90% in AATD liver disease and why screening matters now.

Low-frequency cannabis use was linked to 23% higher odds of self-reported cardiovascular disease and 40% higher odds of stroke in a BRFSS analysis.

Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.

Timucin Taner, MD, PhD, explains how to reduce long-term immunosuppression after liver transplant, who to start with, and why biomarkers remain the gap.

Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease.

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

Zobair Younossi, MD, MPH, discusses MAESTRO-NAFLD-1 data linking resmetirom to improved worry and health distress scores in compensated MASH cirrhosis.

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

Quantitative HBsAg testing now determines which patients on antiviral therapy may qualify for bepirovirsen, a finite add-on treatment for chronic hepatitis B.

Marlyn Mayo, MD, discusses long-term seladelpar data linking IL-31 reductions to PBC pruritus improvement and why the cytokine is not ready to guide treatment.

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.

Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.

IL-33 has 2 forms in COPD: oxidized IL-33 drives mucus dysfunction, while reduced IL-33 recruits inflammatory cells, with implications for mucus plugging.

Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.

Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.

Marlyn Mayo, MD, discusses 4-year ELATIVE data on elafibranor sustaining biochemical response across PBC stages, with stable fibrosis markers.

Sebastian outlines a tiered carotid imaging strategy and the CTA findings pointing to dissection, vasculitis, or intraluminal thrombus.

In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.

In ZIPS-2, 20 mg daily zinc reduced all-cause infection rates by 38% vs placebo in Ugandan children with sickle cell anemia aged <5 years.